Teladoc Health, Inc. (NYSE:TDOC) Shares Bought by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. boosted its holdings in shares of Teladoc Health, Inc. (NYSE:TDOC) by 52.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 42,300 shares of the health services provider’s stock after purchasing an additional 14,484 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in Teladoc Health were worth $7,034,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Bellecapital International Ltd. lifted its position in Teladoc Health by 3.3% during the second quarter. Bellecapital International Ltd. now owns 2,054 shares of the health services provider’s stock valued at $342,000 after purchasing an additional 66 shares during the period. Cullen Frost Bankers Inc. increased its holdings in Teladoc Health by 43.9% in the second quarter. Cullen Frost Bankers Inc. now owns 226 shares of the health services provider’s stock valued at $38,000 after buying an additional 69 shares in the last quarter. GPS Wealth Strategies Group LLC increased its holdings in Teladoc Health by 1.5% in the second quarter. GPS Wealth Strategies Group LLC now owns 5,140 shares of the health services provider’s stock valued at $855,000 after buying an additional 74 shares in the last quarter. Eudaimonia Partners LLC increased its holdings in Teladoc Health by 1.9% in the first quarter. Eudaimonia Partners LLC now owns 4,191 shares of the health services provider’s stock valued at $762,000 after buying an additional 77 shares in the last quarter. Finally, Kovack Advisors Inc. increased its holdings in Teladoc Health by 2.2% in the second quarter. Kovack Advisors Inc. now owns 3,675 shares of the health services provider’s stock valued at $611,000 after buying an additional 78 shares in the last quarter. Institutional investors own 79.43% of the company’s stock.

In related news, CFO Mala Murthy sold 3,851 shares of the company’s stock in a transaction that occurred on Friday, June 25th. The shares were sold at an average price of $165.48, for a total transaction of $637,263.48. Following the sale, the chief financial officer now directly owns 21,208 shares of the company’s stock, valued at approximately $3,509,499.84. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jason N. Gorevic sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 3rd. The stock was sold at an average price of $150.12, for a total transaction of $1,501,200.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,321 shares of company stock worth $3,567,368. Company insiders own 6.47% of the company’s stock.

TDOC has been the subject of a number of recent analyst reports. Oppenheimer cut their price objective on shares of Teladoc Health from $250.00 to $220.00 and set an “outperform” rating for the company in a report on Wednesday, July 28th. Craig Hallum cut their price objective on shares of Teladoc Health from $202.00 to $165.00 and set a “hold” rating for the company in a report on Wednesday, July 28th. KeyCorp cut their price objective on shares of Teladoc Health from $220.00 to $180.00 and set an “overweight” rating for the company in a report on Wednesday, July 28th. Deutsche Bank Aktiengesellschaft cut shares of Teladoc Health from a “buy” rating to a “hold” rating and cut their price objective for the company from $225.00 to $153.00 in a report on Wednesday, July 28th. Finally, Barclays cut their target price on shares of Teladoc Health from $240.00 to $170.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 28th. Twelve analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $217.75.

NYSE:TDOC opened at $138.60 on Wednesday. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.00 and a quick ratio of 3.79. The firm has a market capitalization of $22.07 billion, a price-to-earnings ratio of -24.44 and a beta of 0.24. The company’s 50-day moving average is $145.09 and its two-hundred day moving average is $159.22. Teladoc Health, Inc. has a 1-year low of $129.74 and a 1-year high of $308.00.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Tuesday, July 27th. The health services provider reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.27). The firm had revenue of $503.14 million during the quarter, compared to analyst estimates of $499.85 million. Teladoc Health had a negative net margin of 46.86% and a negative return on equity of 1.29%. The business’s revenue for the quarter was up 108.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.34) earnings per share. As a group, equities analysts anticipate that Teladoc Health, Inc. will post -3.53 earnings per share for the current fiscal year.

About Teladoc Health

Teladoc Health, Inc engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure.

Recommended Story: Intrinsic Value and Stock Selection

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.